About the Company
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AERI News
Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of ...
Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?
One such stock that you may want to consider dropping is Aerie Pharmaceuticals, Inc. AERI, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings ...
Alcon eyes $770m takeover of ophthalmology specialist Aerie
Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals in a transaction that values the US company ...
Alcon (ALC) Gains From Robust Contact Lense Sales, Launches
post the acquisition of Aerie Pharmaceuticals, Inc. We note that the ophthalmology industry is highly competitive and, in both surgical and vision care businesses, Alcon faces intense competition.
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
post the acquisition of Aerie Pharmaceuticals, Inc. Alcon price | Alcon Quote The cost of net sales in the quarter was up 6.5% year over year. The core operating margin was 14.2% in the quarter ...
Aerie Pharmaceuticals interview released for Ophthalmic Drugs Conference
SMi Group Reports: Vice President of Aerie Pharmaceuticals to present at SMi’s Ophthalmic Drugs conference commencing on 18 th - 20 th November 2019 in London. The ophthalmic drugs market has ...
Daniel Janney's Net Worth
Inc., AERIE PHARMACEUTICALS INC, VIVEVE MEDICAL, INC., and ELLIE MAE INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second ...
Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
CME Overview
This continuing medical education activity is provided by OSN New York 2020 is supported, in part, by independent medical education grants from Aerie Pharmaceuticals, Inc.; Alcon Vision ...
CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...
RCKT Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...